ENETS Webinar Header 1920 350px
Webinar

Resistance to somatostatin analogues - Progress in the management of SSA

This session will address the challenge of resistance to somatostatin analogues (SSA) in neuroendocrine neoplasms (NEN). Expert talks will explore strategies for managing resistance and selecting appropriate subsequent lines of treatment, alongside emerging therapeutic options with novel SRLs. The programme will feature interactive clinical case presentations, where participants can vote and engage in real-time decision-making. The session will conclude with a multidisciplinary panel discussion to examine key issues and practical perspectives.

This free webinar is open to all healthcare professionals. Registration is required in advance. Click the button below to access the Zoom registration link and reserve your spot.

 

Educational Level:

Advanced

Keywords:

somatostatin receptor ligands, second-line therapy, PRRT, targeted therapy, tumour biology

Downloads:

Agenda:

Moderator: Antongiulio FAGGIANO, ITA

18:00 – 18:05 Opening comments – Antongiulio FAGGIANO, ITA

18:05 – 18:20 Talk 1: Resistance to SSA - how to address it and which should be the second/next lines – Rachel RIECHELMANN, BRA

18:20 – 18:35 Talk 2: Novel SRLs in NEN – Hans HOFLAND, NED

18:35 – 18:50 Case presentations – Maribel DEL OLMO, ESP

18:50 – 19:05 Discussion

19:05 – 19:10 Closing comments – Antongiulio FAGGIANO, ITA

Moderators:

Antongiulio Faggiano
Antongiulio Faggiano

Speakers:

Rachel Riechelmann
Rachel Riechelmann
Hans Hofland
Hans Hofland
Maribel del Olmo
Maribel del Olmo

The webinar series is intended for HCPs qualified by law to prescribe medicine.

 
 

Conflict of Interest Disclosure

In line with EACCME® standards, all faculty participating in this webinar have disclosed any potential conflicts of interest. The disclosures are available to all participants before and during the webinar session.

  • Antongiulio FAGGIANO (moderator) reports the following potential conflicts of interest:
    • Receipt of grants/research supports: Ipsen, Novartis, Recordati rare diseases, Istituto Gentili
    • Receipt of honoraria or consultation fees: Ipsen
  • Rachel RIECHELMANN (speaker) reports the following potential conflicts of interest:
    • Participation in a company sponsored speaker's bureau: Honorary for lectures and advisory board from Ipsen.
  • Hans HOFLAND (speaker) reports the following potential conflicts of interest:
    • Receipt of honoraria or consultation fees: Novartis, Serb, Ipsen
  • Maribel DEL OLMO (speaker) reports the following potential conflicts of interest:
    • Receipt of honoraria or consultation fees: IPSEN, NOVARTIS, ITM, PFIZER.
    • Participation in a company sponsored speaker’s bureau: ITM, NOVARTIS, IPSEN

 

UEMS- EACCME® Accreditation Statement

The Webinar Resistance to somatostatin analogues - Progress in the management of SSA, Virtual, Germany, 24/09/2025 - 24/09/2025, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 1.0 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at https://edhub.ama-assn.org/pages/applications.

Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.
Back to webinar archive